Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This is a randomized, double-blind, placebo-controlled, multi-arm, multicenter, phase II trial design to allow a rapid efficacy and toxicity assessment of potential therapies (camostat mesilate and artemisia annua) immediately after COVID-19 positive testing in mild to moderate disease and high-risk factors such as diabetes, hypertension, and obesity among others.
Epistemonikos ID: db1d68cb8fc238c02066af5036083f0bb5da6ada
First added on: Aug 29, 2020